High-Flow Nasal Cannula in COVID-19 Patients With Moderate to Severe Respiratory Distress: A Retrospective Analysis

Lubna Saffarini; Nour Sabobeh; Chafika Lasfer; Sara Kazim

doi:10.7759/cureus.52518

High-Flow Nasal Cannula in COVID-19 Patients With Moderate to Severe Respiratory Distress: A Retrospective Analysis

Cureus. 2024 Jan 18;16(1):e52518. doi: 10.7759/cureus.52518. eCollection 2024 Jan.

Authors

Lubna Saffarini¹, Nour Sabobeh¹, Chafika Lasfer², Sara Kazim¹

Affiliations

¹ Emergency Department, Rashid Hospital, Dubai, ARE.
² Emergency Medicine Department, Fakeeh University Hospital, Dubai, ARE.

Abstract

Background: A high-flow nasal cannula (HFNC) is a device for non-invasive ventilation (NIV). It was utilized during the COVID-19 pandemic in patients with moderate to severe respiratory distress due to its benefit profile in delaying intubation, ease of use, and comfort of patients in comparison to NIV.

Objectives: Our main objective is to calculate the intubation rate of patients with suspected or lab-confirmed COVID-19 in moderate to severe respiratory distress who failed graded oxygen therapy (GOT). Before incorporating HFNC as a treatment option, the intubation rate was 100% after GOT failure. We calculated the rate of intubation at two, six, and 12 hours of starting HFNC, where each patient is in their own control with an assumed intubation rate of 100%. Other objectives include measuring the rate of improvement of the ROX index, respiratory rate (RR), and oxygen saturation (SPO2) levels at two, six, and 12 hours.

Methods: We retrospectively screened patients with suspected or lab-confirmed COVID-19 infection in moderate to severe respiratory distress at Rashid Hospital Trauma Center, Emergency Department in Dubai, United Arab Emirates, from April 10, 2020, until December 31, 2020. The list of patients was pooled from the SALAMA electronic system.

Results: A total of 121 patients were included in the analysis. Assuming an intubation rate of 100% at 0 hours (end of GOT), after starting HFNC, the intubation rate (primary outcome) at two hours was 7.43% (9/121), at six hours was 7.14% (8/112), and at 12 hours was 5.77% (6/104). The total intubation rate at 12 hours was 19% (23/121). The use of HFNC was also shown to improve the ROX index, RR, and SPO2 at two, six, and 12 hours.

Conclusion: In patients with suspected or lab-confirmed COVID-19 in moderate to severe respiratory distress who failed GOT and were started on HFNC, it was noted that the intubation rate decreased from an assumed rate of 100% to 19% at 12 hours from starting the treatment. There was also a statistically significant improvement in the ROX index, SPO2, and RR at two, six, and 12 hours from the initiation at 0 hours.

Keywords: covid-19; high-flow nasal cannula (hfnc); oxygen support; respiratory distress; rox index.